InVivoSIM anti-human CXCL10 (IP-10) (Eldelumab Biosimilar)
Catalog #SIM0076
Clone:
Eldelumab
Product Details
This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody, eldelumab, making it ideal for research use. Eldelumab is a humanized IgG1, k monoclonal antibody that specifically binds the pro-inflammatory cytokine C-X-C motif chemokine ligand 10 (CXCL10), also known as 10 kDa interferon gamma-induced protein (gamma-IP10 or IP-10). Importantly, the Fc of the eldelumab antibody is engineered to replace lysine (K) at position 214 with arginine (R) to reduce the Fc effector function (i.e., to lower the ADCC or CDC activity of the antibody). CXCL10 is a secreted protein that is mainly produced by cancer cells, endothelial cells, fibroblasts, and monocytes in response to IFN-gamma secretion. CXCL10 binds its only receptor, CXCR3, to activate Src, PI3K-AKT, Erk1/2, MAKP, and other downstream pathways. The CXCL10-CXCR3 axis activates G protein-mediated signaling, leading to the recruitment of activated Th1 lymphocytes to inflammatory sites, including tumors, brain injury, and viral or Toxoplasma gondii infections. In tumors, CXCL10-CXCR3 regulates immune cell activation, differentiation, and migration to promote anti-tumor immunity through paracrine signaling. The tumor-derived CXCL10 molecules, on the contrary, interact with CXCR3, thereby inducing cancer cell proliferation, tumor angiogenesis, and other pro-cancerous effects. During brain injury, the CXCL10/CXCR3 axis is involved in the activation and recruitment of microglia to the lesion sites, which is an essential element for neuronal reorganization. In experiments involving CXCL10-stimulated human PBMCs, NF-ĪŗB-overexpressing human umbilical vein endothelial cells (HUVECs), and CXCR3-expressing cells, in vitro treatment with eldelumab antibody is reported to neutralize the CXCL10 activity.Specifications
| Isotype | Human IgG1, Īŗ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | K214R |
| Immunogen | Human CXCL10 |
| Reported Applications |
in vivo functional assays in vitro functional assays Flow cytometry ELISA |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
<0.5EU/mg (<0.0005EU/Ī¼g) Determined by LAL gel clotting assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
>95% Determined by SDS-PAGE |
| Sterility | 0.2 Āµm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theilerās Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze. |
Recommended Products
-
Recommended Isotype Control(s)
RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme
-
Recommended Dilution Buffer
InVivoPure pH 7.0 Dilution Buffer